DK3299466T3 - Fusokiner, der involverer cytokiner med kraftigt reducerede receptorbindingsaffiniteter - Google Patents
Fusokiner, der involverer cytokiner med kraftigt reducerede receptorbindingsaffiniteter Download PDFInfo
- Publication number
- DK3299466T3 DK3299466T3 DK17195867T DK17195867T DK3299466T3 DK 3299466 T3 DK3299466 T3 DK 3299466T3 DK 17195867 T DK17195867 T DK 17195867T DK 17195867 T DK17195867 T DK 17195867T DK 3299466 T3 DK3299466 T3 DK 3299466T3
- Authority
- DK
- Denmark
- Prior art keywords
- effinities
- fusokines
- receptor binding
- reduced receptor
- involving cytokines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306034 | 2013-07-18 | ||
| EP14734831.2A EP3022305B1 (en) | 2013-07-18 | 2014-07-03 | Fusokines involving cytokines with strongly reduced receptor binding affinities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3299466T3 true DK3299466T3 (da) | 2019-11-18 |
Family
ID=48906191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17195867T DK3299466T3 (da) | 2013-07-18 | 2014-07-03 | Fusokiner, der involverer cytokiner med kraftigt reducerede receptorbindingsaffiniteter |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10640542B2 (da) |
| EP (2) | EP3299466B1 (da) |
| JP (2) | JP6580037B2 (da) |
| KR (1) | KR102322510B1 (da) |
| CN (2) | CN105705641B (da) |
| AU (2) | AU2014292371B2 (da) |
| BR (1) | BR112016001036B1 (da) |
| CA (1) | CA2917937C (da) |
| DK (1) | DK3299466T3 (da) |
| ES (2) | ES2757501T3 (da) |
| HK (1) | HK1252831A1 (da) |
| IL (1) | IL243451B (da) |
| MX (1) | MX2016000611A (da) |
| SG (2) | SG11201600163VA (da) |
| WO (1) | WO2015007536A2 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CA3013551A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Clec9a binding agents and use thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| WO2017153402A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CA3023881A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
| WO2018077893A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| AU2018216032B2 (en) | 2017-02-06 | 2022-04-07 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
| JP2020505955A (ja) | 2017-02-06 | 2020-02-27 | オリオンズ バイオサイエンス インコーポレイテッド | 標的化改変型インターフェロン及びその使用 |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| WO2019032663A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | PD-1 AND PD-L1 BINDING AGENTS |
| CN111511763A (zh) | 2017-08-09 | 2020-08-07 | 奥里尼斯生物科学有限公司 | Cd8结合剂 |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| CN113767115A (zh) | 2019-03-28 | 2021-12-07 | 奥里尼斯生物科学股份有限公司 | 治疗性干扰素α1蛋白 |
| EP4329786A1 (en) * | 2021-04-30 | 2024-03-06 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002754A1 (en) | 1989-08-22 | 1991-03-07 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| WO2002044394A2 (en) * | 2000-11-29 | 2002-06-06 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| AU2002357784B2 (en) * | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| WO2006053883A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| WO2008014612A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| EP2173377B1 (en) | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| CN108129573B (zh) | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| EP2367840B1 (en) | 2008-12-08 | 2015-08-12 | Complix N.V. | Single-chain antiparallel coiled coil proteins |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| EP2475397A1 (en) | 2009-09-10 | 2012-07-18 | Cytos Biotechnology AG | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| CN105031618A (zh) * | 2009-11-02 | 2015-11-11 | 加利福尼亚大学董事会 | 用于细胞因子递送的穹窿体复合物 |
| SG188160A1 (en) * | 2009-12-23 | 2013-03-28 | Gradalis Inc | Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
| JP2013524807A (ja) * | 2010-04-22 | 2013-06-20 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド | 高親和性レプチン及びレプチンアンタゴニスト |
| CN102372780A (zh) * | 2010-08-23 | 2012-03-14 | 上海市计划生育科学研究所 | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| KR102037541B1 (ko) | 2011-10-28 | 2019-10-29 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| CA2861927C (en) * | 2012-01-20 | 2021-01-26 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| DK2822575T3 (da) | 2012-03-03 | 2020-06-15 | Immungene Inc | Manipulerede, muterede antistof-interferon-fusionsmolekyler |
| EA037749B1 (ru) * | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
-
2014
- 2014-07-03 ES ES17195867T patent/ES2757501T3/es active Active
- 2014-07-03 CA CA2917937A patent/CA2917937C/en active Active
- 2014-07-03 MX MX2016000611A patent/MX2016000611A/es active IP Right Grant
- 2014-07-03 JP JP2016526515A patent/JP6580037B2/ja active Active
- 2014-07-03 BR BR112016001036-1A patent/BR112016001036B1/pt active IP Right Grant
- 2014-07-03 EP EP17195867.1A patent/EP3299466B1/en active Active
- 2014-07-03 KR KR1020167002676A patent/KR102322510B1/ko active IP Right Grant
- 2014-07-03 CN CN201480040538.3A patent/CN105705641B/zh active Active
- 2014-07-03 WO PCT/EP2014/064227 patent/WO2015007536A2/en active Application Filing
- 2014-07-03 ES ES14734831.2T patent/ES2657060T3/es active Active
- 2014-07-03 EP EP14734831.2A patent/EP3022305B1/en active Active
- 2014-07-03 US US14/905,343 patent/US10640542B2/en active Active
- 2014-07-03 DK DK17195867T patent/DK3299466T3/da active
- 2014-07-03 CN CN201911159381.7A patent/CN110835376B/zh active Active
- 2014-07-03 SG SG11201600163VA patent/SG11201600163VA/en unknown
- 2014-07-03 AU AU2014292371A patent/AU2014292371B2/en active Active
- 2014-07-03 SG SG10201808738WA patent/SG10201808738WA/en unknown
-
2016
- 2016-01-03 IL IL24345116A patent/IL243451B/en active IP Right Grant
-
2018
- 2018-06-01 AU AU2018203868A patent/AU2018203868B2/en active Active
- 2018-08-14 US US16/103,302 patent/US11358997B2/en active Active
- 2018-09-20 HK HK18112159.2A patent/HK1252831A1/zh unknown
-
2019
- 2019-08-27 JP JP2019154901A patent/JP6853317B2/ja active Active
-
2022
- 2022-04-29 US US17/733,026 patent/US20230054612A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3299466T3 (da) | Fusokiner, der involverer cytokiner med kraftigt reducerede receptorbindingsaffiniteter | |
| DK3083694T3 (da) | Caniniserede, murine anti-canin-pd-1-antistoffer | |
| FR3006466B3 (fr) | . | |
| BR302014001376S1 (pt) | Configuração aplicada em bolsa. | |
| DK3178928T3 (da) | Pint-knockout-mus med en præmatur, aldersassocieret fænotype | |
| DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
| DK3044389T3 (da) | Vinduespost-tværstykke-konstruktion | |
| FR3001302B1 (fr) | . | |
| BR112016002722A2 (pt) | andaime | |
| DK3080385T3 (da) | Forbedret lukkeapparat | |
| FI10647U1 (fi) | Ruuvipuristin | |
| FR3001303B1 (fr) | . | |
| BR112016010589A2 (pt) | Plastificantes para polímeros | |
| GB2513316B (en) | Wedge mechanism | |
| UA27168S (uk) | Мобільний телефон | |
| UA28910S (uk) | Степлер | |
| CL2015002282S1 (es) | Encendedor | |
| CL2013003511S1 (es) | Carpeta | |
| BR302013006726S1 (pt) | Configuração aplicada em móvel do tipo estante | |
| FI10266U1 (fi) | Vaneri | |
| DK2994714T3 (da) | Forbedret opto-pyroteknisk initiator | |
| CL2014000658S1 (es) | Barandas | |
| ES1079187Y (es) | Babero perfeccionado | |
| ES1078661Y (es) | Cometa perfeccionada | |
| BR302014001579S1 (pt) | Configuração aplicada em telefone |